The dermatology drugs market includes medications that are used for the treatment of skin conditions such as dermatitis (including eczema), rosacea, hyperhidrosis, androgenic alopecia, onychomycosis, hair loss, acne, immune disorders (including psoriasis), microbial infections (bacterial, fungal, and viral), vascular and pigmented lesion removal, common warts, seborrheic keratosis, and other skin diseases.
The global dermatology drugs market was valued at around $32 billion in 2017. North America was the largest region in the dermatology drugs market in 2017, accounting for around 31% market share. The USA was the largest country in the market in 2017, accounting for over 24% market share.
Pharmaceutical companies are offering new drugs referred to as immune modulators for the treatment of skin diseases such as eczema. Eczema is a chronic skin condition caused by the lack of skin proteins that results in inflammation and irritation in the skin. These drugs are used to externally treat the skin without changing the immune system of the body. In addition, unlike topical steroids, these new medications do not cause thinning of the skin and breaking of superficial blood vessels. Tacrolimus (Protopic) and Pimecrolimus (Elidel) are major drugs available for the treatment of eczema.
The top five companies covered are Johnson & Johnson, Allergan Plc., Galderma S.A, Novartis AG and GlaxoSmithKline Plc. Johnson & Johnson (J&J) was the largest company in the dermatology drugs market in 2017.
The countries covered are USA, China, Germany, Brazil, Japan, UK, Spain, Russia, France, Australia, Italy, India and rest of the world.
The dermatology drugs market includes Skin Cleansers, Emollients, OTC Dermatological Drugs, Ointments, Pastes and Gels.